Bulk Pharmaceutical API Sources for VERMOX

Bulk Pharmaceutical API Sources for VERMOX

Vendor	Vendor Homepage	Vendor Sku	API Url
ChemExper Chemical Directory		jfcq`@LLxAGdfWeUWnUEHubuZij@I`@@@@@
ChemBridge		5250893
ASINEX		BAS 00341140
Hangzhou Trylead Chemical Technology		TL8002405
NovoSeek		4030
Vitas-M Laboratory		STK093862

VERMOX Bulk Active Pharmaceutical Ingredient (API) Sourcing and Patent Landscape

Last updated: February 19, 2026

This report analyzes the global sourcing landscape for mebendazole, the active pharmaceutical ingredient (API) in Vermox, focusing on key manufacturers, regulatory approvals, and the patent status of the drug and its manufacturing processes. Demand for mebendazole is driven by its efficacy in treating a range of parasitic worm infections, particularly in regions with high prevalence rates.

What is Mebendazole and Its Therapeutic Use?

Mebendazole is a broad-spectrum benzimidazole anthelmintic agent. It is indicated for the treatment of infections caused by various nematodes, including pinworm, roundworm, hookworm, and whipworm. The drug functions by inhibiting the polymerization of tubulin in the intestinal cells of parasitic worms, disrupting glucose uptake and depleting glycogen stores. This leads to the immobilization and death of the parasites. Mebendazole is typically administered orally.

Global Mebendazole API Manufacturers

The production of mebendazole API is concentrated among a limited number of manufacturers, primarily located in Asia. These suppliers cater to both generic drug manufacturers and, in some cases, directly to pharmaceutical companies for finished dosage formulations. Key considerations for sourcing include Good Manufacturing Practice (GMP) compliance, regulatory filings (e.g., Drug Master Files - DMFs), and production capacity.

Manufacturer	Country of Origin	Key Certifications/Filings	Notes
Jubilant Life Sciences	India	US FDA, EDQM, WHO-GMP	Large-scale producer with a diverse API portfolio.
Dr. Reddy's Laboratories	India	US FDA, EDQM, TGA, Health Canada	Established API supplier with a strong regulatory track record.
Sun Pharmaceutical Industries	India	US FDA, EDQM, WHO-GMP	Major global pharmaceutical company with significant API manufacturing.
Cipla Ltd.	India	US FDA, EDQM, WHO-GMP	Extensive experience in generic API production.
Huiyi (Hubei) Fine Chemical Co., Ltd.	China	Chinese GMP, potential for other international filings	Emerging player in the API market, may require additional due diligence.
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.	China	US FDA, EDQM, PMDA, WHO-GMP	Significant API producer with a focus on quality and regulatory compliance.
Sumitomo Chemical Co., Ltd.	Japan	PMDA, US FDA (potentially for specific product lines)	Known for high-quality standards, may operate in specialized segments.

Note: The certifications listed are indicative and may vary for specific mebendazole API batches or facilities. Manufacturers often hold multiple site-specific and product-specific regulatory approvals.

Regulatory Approvals and DMF Filings

The regulatory landscape for API sourcing is critical for pharmaceutical companies. A Drug Master File (DMF) is a submission to a regulatory agency (such as the U.S. Food and Drug Administration - FDA) that contains detailed information about the manufacturing, processing, packaging, and storing of a drug substance.

• U.S. FDA: Manufacturers seeking to supply mebendazole API for drugs marketed in the United States must typically have a Type II DMF on file with the FDA. This allows the FDA to review the API manufacturing details when a finished drug product application referencing the DMF is submitted [1].
• European Medicines Agency (EMA) / EDQM: In Europe, the European Directorate for the Quality of Medicines & HealthCare (EDQM) issues Certificates of Suitability (CEP) to the monographs of the European Pharmacopoeia. A CEP signifies that the API complies with the European Pharmacopoeia monograph and facilitates its use in Marketing Authorisation Applications (MAAs) within Europe [2].
• Other Regulatory Bodies: Agencies in Canada (Health Canada), Australia (Therapeutic Goods Administration - TGA), and Japan (Pharmaceuticals and Medical Devices Agency - PMDA) have their own requirements, often involving DMFs or equivalent documentation. World Health Organization Good Manufacturing Practice (WHO-GMP) is a widely recognized standard.

Key DMF Holders (Indicative): While a comprehensive real-time list is proprietary and subject to change, major API manufacturers like Jubilant Life Sciences, Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, and Zhejiang Jiuzhou Pharmaceutical are known to maintain DMFs for mebendazole with major regulatory authorities. Companies sourcing mebendazole API should always verify the current status and acceptance of the DMF by the relevant regulatory body for their specific market.

Patent Landscape Analysis

The patent landscape for mebendazole, as a molecule, is largely historical. Mebendazole was first patented in the early 1970s. However, its composition of matter patents have long since expired, allowing for generic competition. The focus of current patent activity often shifts to manufacturing processes, novel polymorphic forms, and specific formulations that may offer improved efficacy, stability, or delivery.

Mebendazole (Active Ingredient) Patent Status

• Composition of Matter Patents: The original patents covering the mebendazole molecule have expired globally. This has opened the door for generic manufacturers to produce and market mebendazole-based products, provided they meet regulatory requirements.
• Exclusivity Periods: While patent protection for the molecule itself has lapsed, regulatory exclusivities (e.g., data exclusivity, orphan drug exclusivity if applicable for specific indications) may still exist for certain branded formulations or new uses, but these are distinct from patent protection.

Manufacturing Process Patents

While the molecule is off-patent, novel or improved methods of synthesizing mebendazole can be patented. These patents typically focus on:

• Yield Improvement: Processes that increase the efficiency of mebendazole synthesis, leading to higher yields and lower production costs.
• Purity Enhancement: Methods designed to produce mebendazole with higher levels of purity or to remove specific impurities more effectively.
• Green Chemistry Approaches: Development of more environmentally friendly synthesis routes, using fewer hazardous reagents or solvents.
• Cost Reduction: Innovations that streamline the manufacturing process or utilize cheaper starting materials.

Companies developing new mebendazole API production methods must conduct thorough freedom-to-operate (FTO) analyses to avoid infringing existing process patents. Searches in patent databases (e.g., Espacenet, USPTO, WIPO) using keywords like "mebendazole synthesis," "benzimidazole anthelmintic production," and specific chemical reaction names are necessary.

Example of Process Patent Focus: A hypothetical patent might claim "A process for the preparation of mebendazole comprising reacting compound A with compound B under specific catalytic conditions and a novel purification step." Such claims would require careful evaluation by an IP professional to determine their scope and potential for infringement.

Polymorph and Formulation Patents

Patents can also be sought for:

• Polymorphs: Different crystalline forms (polymorphs) of mebendazole may have distinct physical properties (e.g., solubility, stability, bioavailability). If a specific, novel, and non-obvious polymorph is identified and shown to offer advantages, it can be patented.
• Formulations: New drug delivery systems or formulations of mebendazole that improve its therapeutic profile. This could include sustained-release formulations, improved suspensions, or combination products.

Impact on Sourcing: For API purchasers, understanding the patent status of polymorphs is important. If a specific, patented polymorph is required for a particular formulation, sourcing must be from manufacturers who can supply that exact crystalline form and have the necessary licenses or freedom to operate. Generic formulations, however, typically utilize the most common and well-established polymorphs that are not covered by current, in-force patents.

Market Dynamics and Key Considerations for Sourcing

The market for mebendazole API is largely driven by the demand for generic anthelmintic drugs, particularly in developing countries where parasitic infections are endemic. Pricing is competitive, with supply primarily originating from India and China due to cost advantages in manufacturing.

Key Sourcing Considerations:

1. Quality and Regulatory Compliance: This is paramount. API must meet pharmacopoeial standards (e.g., USP, EP, JP) and be manufactured under cGMP conditions. Verification of current regulatory filings (DMFs, CEPs) and successful audits of manufacturing facilities are essential.
2. Supply Chain Reliability: Ensuring a consistent and uninterrupted supply is critical. This involves assessing the manufacturer's production capacity, historical performance, and contingency plans for supply disruptions.
3. Cost-Effectiveness: While quality is non-negotiable, competitive pricing is a significant factor in the generic API market. Sourcing strategies should aim for a balance between cost and quality.
4. Intellectual Property (IP) Landscape: For new product development or process optimization, understanding the patent landscape for mebendazole synthesis and formulation is vital to ensure freedom to operate.
5. Auditing and Due Diligence: Independent quality audits of API manufacturers are a standard practice for pharmaceutical companies to confirm GMP compliance and assess operational risks.
6. Geopolitical and Economic Factors: Global supply chains can be influenced by trade policies, tariffs, and economic stability in manufacturing regions. Diversifying supplier base where feasible can mitigate risks.

Key Takeaways

• Mebendazole API is primarily manufactured in India and China by established pharmaceutical ingredient suppliers.
• Original composition of matter patents for mebendazole have expired, enabling generic production.
• Current IP focus for mebendazole may be on novel manufacturing processes, specific polymorphic forms, or advanced drug formulations.
• Sourcing decisions must prioritize API quality, cGMP compliance, and robust regulatory documentation (DMFs, CEPs).
• Supply chain reliability and cost competitiveness are critical factors in the generic mebendazole API market.

FAQs

1. What are the primary regulatory requirements for sourcing mebendazole API for the US market?

For the U.S. market, mebendazole API manufacturers must typically have a Type II Drug Master File (DMF) on file with the U.S. Food and Drug Administration (FDA). Pharmaceutical companies seeking to use the API in their finished drug products will reference this DMF in their Abbreviated New Drug Application (ANDA) or New Drug Application (NDA). The FDA reviews the DMF as part of the overall application approval process.

2. How can a company assess the quality and reliability of a mebendazole API supplier?

Quality and reliability are assessed through a multi-pronged approach. This includes verifying the supplier's compliance with current Good Manufacturing Practices (cGMP) through site audits, reviewing their regulatory filings (e.g., DMFs, CEPs) and their acceptance status by relevant health authorities, checking their quality control procedures, and evaluating their supply chain management and track record for consistent delivery. Obtaining samples for independent testing is also standard practice.

3. Are there any active patents that could prevent the generic manufacturing of mebendazole?

The primary patents covering the mebendazole molecule itself have expired. However, companies must conduct freedom-to-operate (FTO) analyses to ensure they are not infringing on patents related to specific manufacturing processes, novel polymorphs, or unique drug formulations that are still under patent protection. Generic manufacturers typically focus on established, non-infringing synthesis routes.

4. What is the typical lead time for sourcing bulk mebendazole API from Asian manufacturers?

Lead times can vary significantly based on the manufacturer's current production schedule, order volume, and inventory levels. Generally, lead times can range from 4 to 12 weeks from order confirmation to delivery. For new suppliers or custom requirements, the lead time might be longer due to initial qualification and setup.

5. How does the price of mebendazole API compare between Indian and Chinese manufacturers?

Both India and China are highly competitive markets for mebendazole API. Historically, manufacturers in both regions have offered cost-effective solutions due to economies of scale and lower manufacturing overheads. Pricing can fluctuate based on raw material costs, production volume, regulatory compliance investments, and global demand. Direct price comparisons require obtaining current quotes from multiple qualified suppliers in both countries.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Drug Master Files (DMFs). Retrieved from [FDA Website - specific URL would be to the DMF guidance page] [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP). Retrieved from [EDQM Website - specific URL would be to the CEP general information page]